---
figid: PMC5384128__13045_2017_455_Fig1_HTML
figtitle: Adaptive resistance and innate resistance
organisms:
- NA
pmcid: PMC5384128
filename: 13045_2017_455_Fig1_HTML.jpg
figlink: /pmc/articles/PMC5384128/figure/Fig1/
number: F1
caption: 'Adaptive resistance and innate resistance. (Left, adaptive resistance) Upon
  recognition of tumor antigens, TILs produce IFN-γ, which induces PD-L1 expression
  via nuclear NF-κB activation and the PKD2 signal pathway. In tumor hypoxia microenvironmental
  condition, HIF-1 regulates the expression of PD-L1 by binding directly to the hypoxia
  response element-4 in the PD-L1 proximal promoter. Upon binding to PD-1, PD-L1 delivers
  a suppressive signal to T cells, leading to T cell dysfunction. (Right, innate resistance)
  Tumor cell PD-L1 expression that might be related to oncogenic signaling pathways
  or oncogenic gene mutation as inherent in the tumor cell. Oncogenic signals (such
  as PI3K/Akt/mTOR, JAK/STAT 3, and EGFR/MAPK pathway) or oncogenic gene mutation
  (such as PTEN, ALK, and EGFR) upregulate PD-L1 expression on tumors as innate resistance.
  Abbreviations: IFN-γ interferon-γ, TILs tumor-infiltrating lymphocytes, NF-κB nuclear
  factor-kappaB, PI3K phosphatidylinositol 3-kinase, HIF-1 hypoxia inducible factor-1,
  JAK/STAT3 Janus kinase/signal transducer and activator of transcription 3, EGFR/MAPK
  epidermal growth factor receptor/mitogen-activated protein kinase, ALK anaplastic
  lymphoma kinase, PKD2 polycystin 2, PD-1 programmed death 1, PD-L1 programmed cell
  death-ligand 1, AKT protein kinase B, mTOR mammalian target of rapamycin, PTEN phosphatase
  and tensin homolog'
papertitle: 'Blocking the PD-1/PD-L1 pathway in glioma: a potential new treatment
  strategy.'
reftext: Song Xue, et al. J Hematol Oncol. 2017;10:81.
year: '2017'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.8343102
figid_alias: PMC5384128__F1
figtype: Figure
organisms_ner:
- Homo sapiens
- Drosophila melanogaster
redirect_from: /figures/PMC5384128__F1
ndex: 87fe8e03-df22-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5384128__13045_2017_455_Fig1_HTML.html
  '@type': Dataset
  description: 'Adaptive resistance and innate resistance. (Left, adaptive resistance)
    Upon recognition of tumor antigens, TILs produce IFN-γ, which induces PD-L1 expression
    via nuclear NF-κB activation and the PKD2 signal pathway. In tumor hypoxia microenvironmental
    condition, HIF-1 regulates the expression of PD-L1 by binding directly to the
    hypoxia response element-4 in the PD-L1 proximal promoter. Upon binding to PD-1,
    PD-L1 delivers a suppressive signal to T cells, leading to T cell dysfunction.
    (Right, innate resistance) Tumor cell PD-L1 expression that might be related to
    oncogenic signaling pathways or oncogenic gene mutation as inherent in the tumor
    cell. Oncogenic signals (such as PI3K/Akt/mTOR, JAK/STAT 3, and EGFR/MAPK pathway)
    or oncogenic gene mutation (such as PTEN, ALK, and EGFR) upregulate PD-L1 expression
    on tumors as innate resistance. Abbreviations: IFN-γ interferon-γ, TILs tumor-infiltrating
    lymphocytes, NF-κB nuclear factor-kappaB, PI3K phosphatidylinositol 3-kinase,
    HIF-1 hypoxia inducible factor-1, JAK/STAT3 Janus kinase/signal transducer and
    activator of transcription 3, EGFR/MAPK epidermal growth factor receptor/mitogen-activated
    protein kinase, ALK anaplastic lymphoma kinase, PKD2 polycystin 2, PD-1 programmed
    death 1, PD-L1 programmed cell death-ligand 1, AKT protein kinase B, mTOR mammalian
    target of rapamycin, PTEN phosphatase and tensin homolog'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - MTOR
  - AKT1
  - AKT2
  - AKT3
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - JAK1
  - JAK2
  - JAK3
  - TYK2
  - MAPK1
  - MAPK3
  - MAPK11
  - MAPK12
  - MAPK13
  - MAPK14
  - MAPK8
  - MAPK9
  - MAPK10
  - EGFR
  - STAT3
  - PTEN
  - ALK
  - SETD2
  - NFKB1
  - PKD2
  - PRKD2
  - PDCD1
  - RPL17
  - RPL17-C18orf32
  - Mtor
  - Tor
  - Akt
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - hop
  - bsk
  - MKP-4
  - p38b
  - rl
  - Egfr
  - Pten
  - Alk
  - tgo
  - sima
  - Dif
  - dl
  - Rel
  - Pkd2
  - CkIIbeta
  - Andorra
  - Anp
  - Acam
  - Cancer
---
